FLT3LG and graft versus host disease: Administration of Flt3L to recipients prior to transplant significantly reduces GvHD, an effect largely attributed to increased numbers of host CD8α+ type 1 conventional DCs (cDC1s) capable of inducing clonal deletion of alloantigen-specific T-cells (21–23).